ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-5.07%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$262M
AUM Growth
+$262M
(-21%)
Cap. Flow
-$50.9M
Cap. Flow
% of AUM
-19.42%
Top 10 Holdings %
Top 10 Hldgs %
60.55%
Holding
81
New
18
Increased
11
Reduced
15
Closed
31
Top Buys
| 1 |
Qiagen
QGEN
|
$16.2M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Icon
ICLR
|
$10.8M |
| 4 |
Zoetis
ZTS
|
$7.07M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$5.82M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$15.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$14.2M |
| 3 |
Orthofix Medical
OFIX
|
$14.2M |
| 4 |
Centene
CNC
|
$12.7M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$9.98M |
Sector Composition
| 1 | Healthcare | 76.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Incyte
INCY
$17B
| $2.37M | 0.83% |
+31,211
| New | +$2.37M |
|
27
SPDR S&P Biotech ETF
XBI
$5.29B
| $2.33M | 0.82% |
31,349
-15,091
| -32% | -$1.12M |
|
28
BioMarin Pharmaceuticals
BMRN
$11.3B
| $2.15M | 0.76% |
+25,975
| New | +$2.15M |
|
29
DexCom
DXCM
$30.9B
| $1.94M | 0.68% |
+26,046
| New | +$1.94M |
|
30
Sutro Biopharma
STRO
$85.6M
| $1.86M | 0.65% |
357,465
+60,957
| +21% | +$318K |
|
31
Fate Therapeutics
FATE
$119M
| $1.78M | 0.62% |
71,640
+11,908
| +20% | +$295K |
|
32
Arcus Biosciences
RCUS
$1.24B
| $1.64M | 0.58% |
64,756
+26,106
| +68% | +$662K |
|
33
Cencora
COR
$57.2B
| $1.63M | 0.57% |
+11,515
| New | +$1.63M |
|
34
Merit Medical Systems
MMSI
$5.34B
| $1.1M | 0.39% |
+20,223
| New | +$1.1M |
|
35
Acadia Healthcare
ACHC
$2.15B
| $1.1M | 0.38% |
+16,189
| New | +$1.1M |
|
36
Zimmer Biomet
ZBH
$20.8B
| $1.05M | 0.37% |
+9,949
| New | +$1.05M |
|
|
ALBO
37
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $751K | 0.26% |
37,835
-82,999
| -69% | -$1.65M |
|
|
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $674K | 0.24% |
+8,454
| New | +$674K |
|
39
Maravai LifeSciences
MRVI
$341M
| $654K | 0.23% |
+23,015
| New | +$654K |
|
40
Axsome Therapeutics
AXSM
$6.09B
| $584K | 0.2% |
15,246
-85,053
| -85% | -$3.26M |
|
41
ADC Therapeutics
ADCT
$370M
| $469K | 0.16% |
+58,967
| New | +$469K |
|
42
Cytokinetics
CYTK
$5.98B
| $453K | 0.16% |
+11,538
| New | +$453K |
|
43
Biodesix
BDSX
$61.9M
| $214K | 0.08% |
130,753
| – | – |
|
44
Praxis Precision Medicines
PRAX
$980M
| $194K | 0.07% |
5,273
-24
| -0.5% | -$883 |
|
45
Immunic
IMUX
$79.4M
| $106K | 0.04% |
30,591
-99,976
| -77% | -$346K |
|
46
Viridian Therapeutics
VRDN
$1.59B
| – | – |
-83,217
| Closed | -$1.54M |
|
47
Vertex Pharmaceuticals
VRTX
$102B
| – | – |
-6,982
| Closed | -$1.82M |
|
|
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-15,342
| Closed | -$1.95M |
|
49
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
|
AFMD
50
DELISTED
Affimed
AFMD
| – | – |
-35,449
| Closed | -$1.55M |
|